Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.
about
Cell signaling by receptor tyrosine kinasesNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?In vitro and in vivo models for analysis of resistance to anticancer molecular therapiesPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesAcquired resistance to EGFR-targeted therapies in colorectal cancerMechanisms of resistance to anti-EGFR therapy in colorectal cancerAntitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsEpidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.Understanding resistance to EGFR inhibitors-impact on future treatment strategiesAntiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells.AXL mediates resistance to cetuximab therapySynthetic progestins differentially promote or prevent 7,12-dimethylbenz(a)anthracene-induced mammary tumors in sprague-dawley rats.Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma.Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody.Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerMolecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancerExpression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacyPhase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitorsHigh mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugsMiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1.The Role of Vascular Endothelial Growth Factor Receptor-1 Signaling in the Recovery from Ischemia.Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesisAddition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trialsMechanisms of resistance to EGFR tyrosine kinase inhibitors.Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancerAXL is an oncotarget in human colorectal cancer.Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma.Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinomaAngiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancerTreatment of recurrent metastatic head and neck cancer: focus on cetuximab.In vivo effect of an luteinizing hormone-releasing hormone analog on vascular endothelial growth factor and epidermal growth factor receptor expression in mammary tumorsSym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabBiomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
P2860
Q24598357-AF1AE64E-66C9-4449-B725-73476969B142Q26796348-AC1A07D8-9066-4D87-A009-DC8F93F41950Q27014174-4D13DCCE-6675-4B2F-BA25-3C85EB167F47Q27015224-FC8EF116-1BB9-48E1-879E-C07C9AB33972Q27022741-E97FB3D2-8204-4E8E-8D95-59DB282E9C6CQ28074073-64E15204-A925-43BC-808B-80C2E347E5CFQ28478344-8757F781-F7C5-4447-BF14-B2EA729F9922Q30412086-3C14E782-45C9-4BB6-8F97-23A2CDFEFF44Q33622614-B4CE8746-797E-4329-A023-8337A3FE87CAQ33644407-71FBE4F2-FAFA-4F6E-AE3F-52600A684200Q33827053-EC6D296E-D6C2-42B0-8975-D0F77D7B1EF4Q34002839-69AA4DCC-1F8E-47BD-86EB-BEF073C97977Q34088424-920EE639-2F00-4834-8FBD-7C36E2C30612Q34182311-07F1B74F-1F61-41CE-AF4A-D0BD1A60EDE6Q34204829-6C283C1F-B5AC-4B67-92F3-8813ED525EF4Q34304999-03E426C0-AC82-449E-AFAC-8B72FFF4BC9FQ34443645-64CEFA65-A17F-4489-9D6E-21667E57DF35Q34529351-B0539989-7D42-4F25-BA51-3B3F4DACF0B9Q34781970-84884740-BF6B-46B2-99F7-67F1480A7935Q35001415-E6D32220-5BCF-4104-8B4E-286F3A1EF4BBQ35076220-734E34BF-FBA9-4B87-9581-04735146F388Q35105257-6FD32758-FCDD-4629-B01D-34695B66A8EDQ35108333-B574BAAD-4889-4B3F-832C-8C8C9098337EQ35212644-23B91184-A8B8-4F9B-AE22-9CF1D00E7FB3Q35437204-E4E315BC-E7F6-4AD2-82C5-D364FCC867FEQ35672735-7E93988C-52BA-4009-8B1D-DCF6CC29E964Q35680577-0EDFE593-235E-490F-93C0-3D08725EF3E4Q36071752-5D4BDE52-AD0A-4E23-8FFD-EB082793B233Q36129640-C1A07509-34C4-4E05-9F28-B1BC4ABA8F88Q36230665-85407F8F-DC03-43C8-8D53-608C4A5D810BQ36238664-BEDCF496-CAFC-4620-8DF3-28FF77F535BCQ36306149-8D6BF345-911A-435F-9F74-AE87194ACFEFQ36414168-F26CFF96-0BD5-4CB9-A537-067DEF12B14EQ36611697-929C95FC-7B64-4013-87CE-14A945A0D90FQ36909227-DEACED2A-D288-4694-91A9-3A5D03683729Q37081930-DE3CD0E2-B4DF-45BF-BA5B-4C46BC818CBDQ37218978-BD9571FD-5014-4647-A1F0-022310C6C911Q37235589-F9426892-7862-424D-B6CE-306D2243916EQ37285565-2501E3D5-CF04-4B32-8BC4-298B7EB4A9C4Q37378581-4D9D0D5C-ABFC-4095-A735-19B4B0C16196
P2860
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Vascular endothelial growth fa ...... r drugs in human cancer cells.
@en
Vascular endothelial growth fa ...... r drugs in human cancer cells.
@nl
type
label
Vascular endothelial growth fa ...... r drugs in human cancer cells.
@en
Vascular endothelial growth fa ...... r drugs in human cancer cells.
@nl
prefLabel
Vascular endothelial growth fa ...... r drugs in human cancer cells.
@en
Vascular endothelial growth fa ...... r drugs in human cancer cells.
@nl
P2093
P50
P1476
Vascular endothelial growth fa ...... or drugs in human cancer cells
@en
P2093
Roberta Rosa
Roberto Bianco
Sonia Garofalo
Teresa Gelardi
Vincenzo Damiano
P304
P356
10.1158/1078-0432.CCR-07-4905
P407
P50
P577
2008-08-11T00:00:00Z